Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESPIRE: ATR-002 in Adult Hospitalized Patients with COVID-19
2020-004206-59Phase 2Terminated
- Sponsor
- Atriva Therapeutics
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing ATR-002 plus standard of care with Placebo plus standard of care (2 arms). Primary endpoints: Efficacy based on clinical severity status and Time to clinically relevant improvement. Started Sep 2020; status: terminated.
02
Drugs
Zapnometinib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-004206-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004206-59.